Behold.ai vs Qure AI
Two chest radiograph companies separated by the most consequential design decision in imaging AI: whether a human still looks. Behold auto reports films it classifies as high confidence normal, removing them from the worklist entirely, which is genuine autonomy inside a bounded task and one of the few instances of it in this index. Qure triages and flags across the broadest chest radiograph regulatory footprint in the market, and the radiologist still reads. The evidence bar should differ accordingly. An autonomous normal classifier needs its false negative rate at the operating threshold published and revalidated locally, because a missed finding on an auto reported film is seen by nobody, ever. Behold publishes more of those numbers than most, and its regulatory standing across jurisdictions is the thing to settle before deployment.
- It removes studies from the worklist entirely, classifying chest radiographs as high confidence normal and auto reporting them, which is genuine autonomy inside a deliberately bounded task.
- The performance numbers that matter for that autonomy are published in peer reviewed venues rather than asserted, and the confidence threshold is itself the governance mechanism.
- For a service drowning in normal chest films, removing them from the queue is a different economic proposition from reading them faster.
- The regulatory footprint across chest radiography is the broadest in the market, spanning nine products across radiography and computed tomography with published device dossiers.
- It is deployed where reading capacity is thinnest, including public health screening programmes, which is a harder operating environment than a hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than governing it.
Side by Side
| Axis | B Behold.ai |
Q Qure AI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The autonomy difference changes what evidence you should demand: a product that auto reports a study nobody reads needs its false negative rate at the operating threshold published and locally revalidated, because a missed finding is never seen by anyone, while a triage product leaves the radiologist reading every film.
Behold's regulatory standing is multi jurisdictional and unsettled, and its corporate history complicates the identity of the contracting entity, both of which should be established before deployment. Neither publishes pricing, and neither publishes performance stratified by prevalence.